Analysts Offer Insights on Healthcare Companies: Baxter International (BAX) and Ultragenyx Pharmaceutical (RARE)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Baxter International (BAX – Research Report) and Ultragenyx Pharmaceutical (RARE – Research Report).
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Baxter International (BAX)
In a report released today, Travis Steed from Bank of America Securities maintained a Hold rating on Baxter International. The company’s shares closed last Friday at $19.75.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
Currently, the analyst consensus on Baxter International is a Hold with an average price target of $20.70, representing a 10.9% upside. In a report released yesterday, Stifel Nicolaus also maintained a Hold rating on the stock with a $20.00 price target.
See the top stocks recommended by analysts >>
Ultragenyx Pharmaceutical (RARE)
In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Ultragenyx Pharmaceutical. The company’s shares closed last Friday at $21.20.
According to TipRanks.com, Ahmad is a 4-star analyst with an average return of
Ultragenyx Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $54.81, implying a 154.5% upside from current levels. In a report issued on January 30, Morgan Stanley also maintained a Buy rating on the stock with a $50.00 price target.
